Optimizing the HRP-2 in vitro malaria drug susceptibility assay using a reference clone to improve comparisons of Plasmodium falciparum field isolates

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Rutvisuttinunt, Wiriya ^a   Chaorattanakawee, Suwanna ^a   Tyner, Stuart D ^a   Teja Isavadharm, Paktiya ^a   Se, Youry ^a   Yingyuen, Kritsanai ^a   Chaichana, Panjaporn ^a   Bethell, Delia ^a   Walsh, Douglas S ^a   Lon, Chanthap ^a   Fukuda, Mark ^b   Socheat, Duong ^c   Noedl, Harald ^d   Schaecher, Kurt ^a   Saunders, David L ^a  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b Armed Forces Health Surveillance Center   (United States)

^c Ministry of Health Cambodia   (Cambodia)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anti malarial drugs; Drug resistance; Drug susceptibility test; ELISA; HRP 2; Malaria; Plasmodium falciparum

Indexed keywords

ARTEMISIN; ARTESUNATE; CHLOROQUINE; DIHYDROARTEMISININ; MEFLOQUINE;

ANALYTIC METHOD; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CAMBODIA; CLONE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CONCENTRATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FREEZE THAWING; IC 50; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MALARIA FALCIPARUM; MASS SPECTROMETRY; MONOTHERAPY; NONHUMAN; PARASITE CULTIVATION; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; REPRODUCIBILITY; STANDARD; TRANSPORT MEDIUM;

ANTIGENS, PROTOZOAN; ANTIMALARIALS; ARTEMISININS; CHROMATOGRAPHY, LIQUID; CULTURE MEDIA; HUMANS; INHIBITORY CONCENTRATION 50; MALARIA, FALCIPARUM; MASS SPECTROMETRY; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 84866101366     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-325     Document Type: Article

References (29)

1. Artemisinin resistance in Plasmodium falciparum malaria. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, Sam An S, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ, N Engl J Med 2009 361 455 467 10.1056/NEJMoa0808859 19641202
2. Evidence of artemisinin-resistant malaria in western Cambodia. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, N Engl J Med 2008 359 2619 2620 10.1056/NEJMc0805011 19064625
3. A histidine-rich protein 2-based malaria drug sensitivity assay for field use. Noedl H, Attlmayr B, Wernsdorfer WH, Kollaritsch H, Miller RS, AmJTrop Med Hyg 2004 71 711 714 (Pubitemid 40075618)
4. Simple histidine-rich protein 2 double-site sandwich enzyme-linked immunosorbent assay for use in malaria drug sensitivity testing. Noedl H, Bronnert J, Yingyuen K, Attlmayr B, Kollaritsch H, Fukuda M, Antimicrob Agents Chemother 2005 49 3575 3577 10.1128/AAC.49.8.3575-3577.2005 16048989 (Pubitemid 41060624)
5. Histidine-rich protein II: a novel approach to malaria drug sensitivity testing. Noedl H, Wernsdorfer WH, Miller RS, Wongsrichanalai C, Antimicrob Agents Chemother 2002 46 1658 1664 10.1128/AAC.46.6.1658-1664.2002 12019072 (Pubitemid 34535179)
6. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD, Antimicrob Agents Chemother 1979 16 710 718 10.1128/AAC.16.6.710 394674 (Pubitemid 10082023)
7. 3H-hypoxanthine incorporation into fresh and stored blood: implications for resistance determination in P. falciparum malaria. Petersen E, Ann Trop Med Parasitol 1986 80 251 252 3530159 (Pubitemid 16083554)
8. Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay. Co EM, Dennull RA, Reinbold DD, Waters NC, Johnson JD, Antimicrob Agents Chemother 2009 53 2557 2563 10.1128/AAC.01370-08 19349518
9. Performance and reliability of the SYBR Green I based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates. Rason MA, Randriantsoa T, Andrianantenaina H, Ratsimbasoa A, Menard D, Trans R Soc Trop Med Hyg 2008 102 346 351 10.1016/j.trstmh.2008.01.021 18321546
10. Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Johnson JD, Dennull RA, Gerena L, Lopez-Sanchez M, Roncal NE, Waters NC, Antimicrob Agents Chemother 2007 51 1926 1933 10.1128/AAC.01607-06 17371812 (Pubitemid 46903075)
11. Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Bacon DJ, Latour C, Lucas C, Colina O, Ringwald P, Picot S, Antimicrob Agents Chemother 2007 51 1172 1178 10.1128/AAC.01313-06 17220424 (Pubitemid 46586790)
12. Antimalarial drug sensitivity profile of western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay and molecular analysis. Akala HM, Eyase FL, Cheruiyot AC, Omondi AA, Ogutu BR, Waters NC, Johnson JD, Polhemus ME, Schnabel DC, Walsh DS, AmJTrop Med Hyg 2011 85 34 41
13. World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Bacon DJ, Jambou R, Fandeur T, Le Bras J, Wongsrichanalai C, Fukuda MM, Ringwald P, Sibley CH, Kyle DE, Malar J 2007 6 120 10.1186/1475-2875-6-120 17822533 (Pubitemid 47561492)
14. Drug-resistant malaria in Bangladesh: an in vitro assessment. Noedl H, Faiz MA, Yunus EB, Rahman MR, Hossain MA, Samad R, Miller RS, Pang LW, Wongsrichanalai C, AmJTrop Med Hyg 2003 68 140 142 (Pubitemid 38240535)
15. Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. Wein S, Maynadier M, Tran Van Ba C, Cerdan R, Peyrottes S, Fraisse L, Vial H, J Clin Microbiol 2010 48 1651 1660 10.1128/JCM.02250-09 20220159
16. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, Rutvisuttinunt W, Bethell D, Surasri S, Fukuda MM, Socheat D, Chan Thap L, Clin Infect Dis 2010 51 82 e89 10.1086/657120 21028985
17. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. Bethell D, Se Y, Lon C, Tyner S, Saunders D, Sriwichai S, Darapiseth S, Teja-Isavadharm P, Khemawoot P, Schaecher K, Ruttvisutinunt W, Lin J, Kuntawungin W, Gosi P, Timmermans A, Smith B, Socheat D, Fukuda MM, PLoS One 2011 6 19283 10.1371/journal.pone.0019283 21603629
18. In vitro antimalarial drug susceptibility in Thai border areas from 1998-2003. Chaijaroenkul W, Bangchang KN, Mungthin M, Ward SA, Malar J 2005 4 37 10.1186/1475-2875-4-37 16060967 (Pubitemid 41316727)
19. Human malaria parasites in continuous culture. Trager W, Jensen JB, Science 1976 193 673 675 10.1126/science.781840 781840
20. Synchronization of Plasmodium falciparum erythrocytic stages in culture. Lambros C, Vanderberg JP, J Parasitol 1979 65 418 420 10.2307/3280287 383936 (Pubitemid 10222999)
21. A simplified liquid chromatography-mass spectrometry assay for artesunate and dihydroartemisinin, its metabolite, in human plasma. Teja-Isavadharm P, Siriyanonda D, Siripokasupkul R, Apinan R, Chanarat N, Lim A, Wannaying S, Saunders D, Fukuda MM, Miller RS, Weina PJ, Meléndez V, Molecules 2010 15 8747 8768 10.3390/molecules15128747 21124272
22. Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression. Le Nagard H, Vincent C, Mentre F, Le Bras J, Comput Methods Programs Biomed 2011 104 10 18 10.1016/j.cmpb.2010.08.003 20828858
23. Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Kaddouri H, Nakache S, Houze S, Mentre F, Le Bras J, Antimicrob Agents Chemother 2006 50 3343 3349 10.1128/AAC.00367-06 17005815 (Pubitemid 44527508)
24. False-positive results of a Plasmodium falciparum histidine-rich protein 2-detecting malaria rapid diagnostic test due to high sensitivity in a community with fluctuating low parasite density. Bell DR, Wilson DW, Martin LB, AmJTrop Med Hyg 2005 73 199 203 (Pubitemid 41278772)
25. Detection of Plasmodium falciparum histidine-rich protein II in saliva of malaria patients. Wilson NO, Adjei AA, Anderson W, Baidoo S, Stiles JK, AmJTrop Med Hyg 2008 78 733 735 (Pubitemid 351845128)
26. Detection of histidine rich protein 2 and panmalarial ICT Malaria Pf/Pv test antigens after chloroquine treatment of uncomplicated falciparum malaria does not reliably predict treatment outcome in eastern Indonesia. Tjitra E, Suprianto S, Dyer ME, Currie BJ, Anstey NM, AmJTrop Med Hyg 2001 65 593 598 (Pubitemid 33134598)
27. Malaria drug-sensitivity testing: new assays, new perspectives. Noedl H, Wongsrichanalai C, Wernsdorfer WH, Trends Parasitol 2003 19 175 181 10.1016/S1471-4922(03)00028-X 12689648 (Pubitemid 36411974)
28. The SYBR Green I malaria drug sensitivity assay: performance in low parasitemia samples. Vossen MG, Pferschy S, Chiba P, Noedl H, AmJTrop Med Hyg 2010 82 398 401
29. Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. Lim P, Wongsrichanalai C, Chim P, Khim N, Kim S, Chy S, Sem R, Nhem S, Yi P, Duong S, Mey Bouth D, Genton B, Beck H, Gobert JG, Rogers WO, Coppee JY, Fandeur T, Mercereau-Puijalon O, Ringwald P, Le Bras J, Ariey F, Antimicrob Agents Chemother 2010 54 2135 2142 10.1128/AAC.01304-09 20194689